First, props to dcaf7 - I appreciate your updates, too. Couple of questions for dcaf7 and the board: there's an article dated February 14th of this year on the web that says a Phase III trial of selumetinib with ovarian cancer patients would be started "in the next few weeks." Any news on that front? Has that trial started?
Also, there's another article dated March 27th that says that "an international, multicenter phase III clinical trial of selumetinib in advanced thyroid cancer will be launched later this year." That's different from the Phase II trial that you mentioned, right, dcaf7? Any news there?
AZN will have a slew of presentations on Selumetinib at ASCO. Two pivotal Phase III's with Selumetinib will launch this year. They have at least 40 ongoing trials with Selumetinib. Just go to clinicaltrials.gov to check them out. BTW, ASCO abstracts will be released at 6:p.m. this coming Wednesday, May 15th.
P.S. NVS will also launch two pivotal Phase III trials with their ARRY MEK inhibitor, MEK-162, this year as well. NVS will also have presentations at ASCO. And ARRY will be conducting a Phase III trial with MEK-162, also to launch this year. FIVE pivotal Phase III trials in oncology to launch this year.
I just want to say that seeing this intelligent, informative and respectful discussion is much appreciated. There is so much drivel on these Y boards at this time that I'm not sure why I keep coming back. (And I'm long Yhoo also. Things have an odd way of evening out sometimes, however maddening.)
Thanks. As far as I know both Phase 3 studies in ovarian and thyroid cancer that you mentioned are not started yet. Keep in mind that both trials, if started, will not be sponsored by AZN. Not sure how AZN and ARRY will benefit from them. Phase 2 pivotal trial that I mentioned is different and will be conducted by AZN.
I thought it was interesting that Array decided to go to Phase III with MEK-162 instead of Selumetinib for low-grade serous ovarian cancer, despite Selumetinib's strong results. Eight of 52 patients in the Phase II trial had complete responses and the findings were described as a "potentially important breakthrough." The data on slide 10 of the investor presentation is for Selumetinib, not for MEK-162. Are the two MEK inhibitors interchangeable? Anyone care to speculate why they went with MEK-162 instead of Selumetinib?